Cargando…

Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin?

High-grade serous ovarian cancer (HGSOC) is characterized by a TP53 mutation rate of up to 96.7% and associated with a more aggressive tumor biology. The origin of HGSOC is thought to arise either from fallopian tube secretory cells or the ovarian surface epithelium/inclusion cysts, the former with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sukhbaatar, Nyamdelger, Bachmayr-Heyda, Anna, Auer, Katharina, Aust, Stefanie, Deycmar, Simon, Horvat, Reinhard, Pils, Dietmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory Press 2017
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495036/ https://www.ncbi.nlm.nih.gov/pubmed/28679689 http://dx.doi.org/10.1101/mcs.a001461

Ejemplares similares

Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome
por: Auer, Katharina, et al.
Publicado: (2015)

Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer
por: Auer, Katharina, et al.
Publicado: (2016)

Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2016)

Correlation of circular RNA abundance with proliferation – exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2015)

Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer
por: Aust, Stefanie, et al.
Publicado: (2017)

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2014)

EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs
por: Reiner, Agnes T., et al.
Publicado: (2017)

A Global Gene Body Methylation Measure Correlates Independently with Overall Survival in Solid Cancer Types
por: Pils, Dietmar, et al.
Publicado: (2020)

Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium
por: Bachmayr-Heyda, Anna, et al.
Publicado: (2013)

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2012)

NECTIN4 (PVRL4) as Putative Therapeutic Target for a Specific Subtype of High Grade Serous Ovarian Cancer—An Integrative Multi-Omics Approach
por: Bekos, Christine, et al.
Publicado: (2019)

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
por: Bekos, Christine, et al.
Publicado: (2021)

The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer
por: Aust, Stefanie, et al.
Publicado: (2013)

Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression
por: Mota, Alba, et al.
Publicado: (2015)

MDCT-Based Radiomics Features for the Differentiation of Serous Borderline Ovarian Tumors and Serous Malignant Ovarian Tumors
por: Yu, Xin-ping, et al.
Publicado: (2021)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer
por: Aust, Stefanie, et al.
Publicado: (2020)

Prostate-Specific Membrane Antigen (PSMA) Expression in Tumor-Associated Neovasculature Is an Independent Prognostic Marker in Patients with Ovarian Cancer
por: Hofstetter, Gerda, et al.
Publicado: (2022)

MRI appearance of ovarian serous borderline tumors of the micropapillary type compared to that of typical ovarian serous borderline tumors: radiologic-pathologic correlation
por: Nakai, Go, et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Histopathological Patterns of Microinvasion in Ovarian Serous Borderline Tumors
por: CÎRSTEA, A.E., et al.
Publicado: (2018)

EGFR Immunoexpression in Malignant Serous and Mucinous Ovarian Tumors
por: CÎRSTEA, A.E., et al.
Publicado: (2018)

Optimization to detect TP53 mutations in circulating cell-free tumor DNA from patients with serous epithelial ovarian cancer
por: Park, Yu Ran, et al.
Publicado: (2018)

TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer
por: Vitale, Silvia R., et al.
Publicado: (2020)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

Peritoneal Carcinosarcoma and Ovarian Papillary Serous Carcinoma Are the Same Origin: Analysis of TP53 Mutation and Microsatellite Suggests a Monoclonal Origin
por: Woo, Chang Gok, et al.
Publicado: (2014)

Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
por: Tuna, Musaffe, et al.
Publicado: (2019)

Serous Ovarian Carcinoma Recurring as Malignant Mixed Mullerian Tumor
por: Hale, Demir, et al.
Publicado: (2015)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

Tumor microenvironment in ovarian cancer peritoneal metastasis
por: Mei, Shuangshuang, et al.
Publicado: (2023)

Iron Regulation: Macrophages in Control
por: Sukhbaatar, Nyamdelger, et al.
Publicado: (2018)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas
por: Tung, Celestine S., et al.
Publicado: (2009)

Correlation of FOXC1 protein with clinicopathological features in serous ovarian tumors
por: WANG, LU-YING, et al.
Publicado: (2016)

A Rare Case of Ovarian Serous Borderline Tumor with Brain Metastasis
por: Veran-Taguibao, Sonia, et al.
Publicado: (2019)

The Multimodal Ultrasound Features of Ovarian Serous Surface Papillary Borderline Tumor
por: Xie, Lijun, et al.
Publicado: (2022)

Bilateral Ovarian Serous Borderline Tumor with Non-Invasive Endometrial Implants
por: Malham, Melissa Bou, et al.
Publicado: (2023)

Digital Pathology-based Study of Cell- and Tissue-level Morphologic Features in Serous Borderline Ovarian Tumor and High-grade Serous Ovarian Cancer
por: Jiang, Jun, et al.
Publicado: (2021)

A Patient Affected with Serous Ovarian/Peritoneal Carcinoma Carrying the FANCM Mutation
por: Nikolaidi, Adamantia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gbdubvgo1at4trelvgqne9tsg6